When to use which molecular prognostic scoring system in the management of patients with MDS?

Kewan, Tariq; Bewersdorf, Jan Philipp; Gurnari, Carmelo; Xie, Zhuoer; Stahl, Maximilian; Zeidan, Amer M

Kewan, Tariq; Bewersdorf, Jan Philipp; Gurnari, Carmelo; Xie, Zhuoer; Stahl, Maximilian; Zeidan, Amer M.

Afiliação

Kewan T; Department of Hematology and Oncology, Yale University, New Haven, CT, USA.
Bewersdorf JP; Memorial Sloan Kettering Cancer Center, Leukemia Service, Department of Medicine, New York, NY, USA.
Gurnari C; Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, USA; Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
Xie Z; Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.
Stahl M; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
Zeidan AM; Department of Hematology and Oncology, Yale University, New Haven, CT, USA. Electronic address: amer.zeidan@yale.edu.

Best Pract Res Clin Haematol ; 36(4): 101517, 2023 12.

Article em En | MEDLINE | ID: mdl-38092484

Assuntos

Leucemia Mieloide Aguda; Síndromes Mielodisplásicas; Humanos; Prognóstico; Síndromes Mielodisplásicas/diagnóstico; Síndromes Mielodisplásicas/genética; Síndromes Mielodisplásicas/terapia; Leucemia Mieloide Aguda/diagnóstico; Leucemia Mieloide Aguda/genética; Leucemia Mieloide Aguda/terapia; Tomada de Decisão Clínica; Mutação

Palavras-chave

MDS; Molecular markers; Prognosis; Scoring system

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Síndromes Mielodisplásicas / Leucemia Mieloide Aguda Limite: Humans Idioma: En Revista: Best Pract Res Clin Haematol Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google